Objective To evaluate the efficacy of Erigeron breviscapus versus compound Salvia miltiorrhiza in the treatment 〖JP2〗of cerebral infarction by a systematic review. Methods Randomized controlled trials (RCTs) of Erigeron breviscapus in the treatment of cerebral infarction published up to July 2013 were collected by searching CNKI, CBM, Wanfang Data, and VIP, as well as other materials. Two researchers independently screened studies according to inclusion and exclusion criteria and then extracted data. The quality of included studies was assessed by Jadad scale. A meta-analysis was performed using RevMan 5.0. Results A total of 23 RCTs were included. Compared with the compound Salvia miltiorrhiza group, the Erigeron breviscapus group had a more improvement in neurological deficit, a higher response rate, and milder adverse reactions. Conclusion Erigeron breviscapus is effective in treating cerebral infarction and has better efficacy than compound Salvia miltiorrhiza, and it has little adverse effect.